{"id":"cabozantinib-tablets","safety":{"commonSideEffects":[{"rate":"55-65%","effect":"Diarrhea"},{"rate":"40-50%","effect":"Fatigue"},{"rate":"35-45%","effect":"Nausea"},{"rate":"30-40%","effect":"Decreased appetite"},{"rate":"20-30%","effect":"Vomiting"},{"rate":"25-35%","effect":"Hypertension"},{"rate":"15-25%","effect":"Palmar-plantar erythrodysesthesia"},{"rate":"15-25%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabozantinib inhibits multiple receptor tyrosine kinases including MET (hepatocyte growth factor receptor), VEGFR2 (vascular endothelial growth factor receptor 2), and AXL, which are involved in tumor cell proliferation, survival, and angiogenesis. By blocking these pathways, the drug suppresses tumor growth and reduces the formation of new blood vessels that feed tumors. This multi-targeted approach is particularly effective in cancers with MET or VEGFR2 dependency.","oneSentence":"Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:40.065Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Hepatocellular carcinoma"},{"name":"Medullary thyroid cancer"},{"name":"Castration-resistant prostate cancer"}]},"trialDetails":[{"nctId":"NCT04338269","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-28","conditions":"Carcinoma, Renal Cell","enrollment":522},{"nctId":"NCT03945773","phase":"PHASE2","title":"Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-01-08","conditions":"Locally Advanced or Metastatic Renal Cell Carcinoma","enrollment":127},{"nctId":"NCT06502171","phase":"PHASE1","title":"Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas","status":"NOT_YET_RECRUITING","sponsor":"Girish Dhall, MD","startDate":"2026-08-01","conditions":"Neurofibromatosis 1, Plexiform Neurofibroma","enrollment":30},{"nctId":"NCT05425004","phase":"PHASE2","title":"Cabozantinib for Patients With Recurrent or Progressive Meningioma","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-06-01","conditions":"Meningioma","enrollment":24},{"nctId":"NCT04586231","phase":"PHASE3","title":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-25","conditions":"Carcinoma, Renal Cell","enrollment":747},{"nctId":"NCT05048212","phase":"PHASE2","title":"A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-20","conditions":"Brain Metastases, Renal Cell Carcinoma","enrollment":20},{"nctId":"NCT05361434","phase":"","title":"A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2022-09-26","conditions":"Advanced Renal Cell Carcinoma","enrollment":311},{"nctId":"NCT05487859","phase":"PHASE2","title":"Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-12-31","conditions":"Kidney Cancer","enrollment":""},{"nctId":"NCT04963283","phase":"PHASE2","title":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-06-23","conditions":"Colorectal Adenocarcinoma, Colon Cancer, Colon Adenocarcinoma","enrollment":48},{"nctId":"NCT03957551","phase":"PHASE1, PHASE2","title":"Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma","status":"TERMINATED","sponsor":"John Rieth","startDate":"2019-08-27","conditions":"Advanced Metastatic Melanoma","enrollment":28},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":"Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma","enrollment":167},{"nctId":"NCT00596648","phase":"PHASE1, PHASE2","title":"A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Exelixis","startDate":"2008-02-12","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":92},{"nctId":"NCT04820179","phase":"PHASE2","title":"Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2021-10-12","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer","enrollment":30},{"nctId":"NCT05100082","phase":"","title":"Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-11-17","conditions":"Hepatocellular Cancer","enrollment":263},{"nctId":"NCT01658878","phase":"PHASE1, PHASE2","title":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-30","conditions":"Hepatocellular Carcinoma","enrollment":657},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":"Metastatic Prostate Cancer, Prostate Adenocarcinoma","enrollment":575},{"nctId":"NCT03755791","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-06-10","conditions":"Hepatocellular Carcinoma","enrollment":837},{"nctId":"NCT03690388","phase":"PHASE3","title":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-10-05","conditions":"Differentiated Thyroid Cancer","enrollment":187},{"nctId":"NCT05660954","phase":"PHASE2","title":"Cabozantinib In Advanced Radioactive-Iodine Refractory Differentiated Thyroid Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2023-05-25","conditions":"Differentiated Thyroid Cancer","enrollment":41},{"nctId":"NCT01896479","phase":"PHASE4","title":"A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2015-02-25","conditions":"Medullary Thyroid Cancer","enrollment":247},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT05135975","phase":"PHASE2","title":"A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors","status":"RECRUITING","sponsor":"Nationwide Children's Hospital","startDate":"2022-07-20","conditions":"Neuroblastoma, Sarcoma","enrollment":86},{"nctId":"NCT03685448","phase":"PHASE2","title":"ANZUP - Non-clear Cell Post Immunotherapy CABozantinib (UNICAB)","status":"COMPLETED","sponsor":"Australian and New Zealand Urogenital and Prostate Cancer Trials Group","startDate":"2019-04-11","conditions":"Renal Cell Carcinoma, Papillary Renal Cell Carcinoma Type 1, Papillary Renal Cell Carcinoma Type 2","enrollment":35},{"nctId":"NCT04400474","phase":"PHASE2","title":"Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study","status":"COMPLETED","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2020-10-07","conditions":"Neuroendocrine Tumor, Anaplastic Thyroid Cancer, Adenocarcinoma","enrollment":93},{"nctId":"NCT05127824","phase":"PHASE2","title":"Autologous Dendritic Cell Vaccine in Kidney Cancer","status":"RECRUITING","sponsor":"Jodi Maranchie","startDate":"2023-07-06","conditions":"Carcinoma, Renal Cell","enrollment":42},{"nctId":"NCT04804813","phase":"","title":"Survey of Cabozantinib Used To Treat People With Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-03-29","conditions":"Renal Cell Carcinoma","enrollment":388},{"nctId":"NCT03149822","phase":"PHASE1, PHASE2","title":"Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-09-28","conditions":"Metastatic Renal Cell Carcinoma","enrollment":45},{"nctId":"NCT05249114","phase":"PHASE1","title":"Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Providence Health & Services","startDate":"2022-12-28","conditions":"Neuroendocrine Tumors","enrollment":6},{"nctId":"NCT04522908","phase":"PHASE2","title":"Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function","status":"COMPLETED","sponsor":"Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest","startDate":"2020-10-12","conditions":"Hepatocellular Carcinoma (HCC), Second Line Treatment","enrollment":40},{"nctId":"NCT03634540","phase":"PHASE2","title":"A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2018-09-27","conditions":"Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC), Kidney Cancer","enrollment":118},{"nctId":"NCT03612232","phase":"PHASE2","title":"Cabozantinib in Advanced Adrenocortical Carcinoma","status":"UNKNOWN","sponsor":"Wuerzburg University Hospital","startDate":"2019-06-04","conditions":"Adrenocortical Carcinoma","enrollment":37},{"nctId":"NCT05265988","phase":"PHASE2","title":"Multiparametric Assessment of Bone Response in mCRPC Patients Treated With Cabozantinib","status":"COMPLETED","sponsor":"Alfredo Berruti","startDate":"2021-11-29","conditions":"Carcinoma Prostate","enrollment":32},{"nctId":"NCT02293980","phase":"PHASE1","title":"A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2014-11-25","conditions":"ccRCC, RCC, Kidney Cancer","enrollment":110},{"nctId":"NCT01755195","phase":"PHASE2","title":"Cabozantinib for Adults With Advanced Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2013-01-15","conditions":"Refractory Soft Tissue Sarcomas","enrollment":55},{"nctId":"NCT03586973","phase":"PHASE2","title":"A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2018-08-06","conditions":"Advanced Hepatocellular Carcinoma","enrollment":34},{"nctId":"NCT03428217","phase":"PHASE2","title":"CANTATA: CB-839 With Cabozantinib vs. Cabozantinib With Placebo in Patients With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Calithera Biosciences, Inc","startDate":"2018-04-24","conditions":"Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma","enrollment":444},{"nctId":"NCT03419572","phase":"","title":"Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-04-24","conditions":"Renal Cell Carcinoma","enrollment":689},{"nctId":"NCT03542877","phase":"PHASE2","title":"Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Academic Thoracic Oncology Medical Investigators Consortium","startDate":"2018-06-01","conditions":"Colorectal Cancer","enrollment":44},{"nctId":"NCT03339219","phase":"PHASE2","title":"A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-12-13","conditions":"Advanced Renal Cell Carcinoma","enrollment":35},{"nctId":"NCT01908426","phase":"PHASE3","title":"Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib","status":"COMPLETED","sponsor":"Exelixis","startDate":"2013-09-26","conditions":"Hepatocellular Carcinoma","enrollment":707},{"nctId":"NCT01865747","phase":"PHASE3","title":"A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma","status":"COMPLETED","sponsor":"Exelixis","startDate":"2013-06","conditions":"Renal Cell Carcinoma","enrollment":658},{"nctId":"NCT03729297","phase":"PHASE2","title":"Cabozantinib in Advanced Salivary Gland Cancer Patients","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2018-09-05","conditions":"Salivary Gland Cancer","enrollment":25},{"nctId":"NCT04644432","phase":"PHASE2","title":"Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma","status":"UNKNOWN","sponsor":"Herlev and Gentofte Hospital","startDate":"2020-03-06","conditions":"Metastatic Renal Cell Carcinoma, Kidney Neoplasm, Urologic Neoplasms","enrollment":30},{"nctId":"NCT04435977","phase":"PHASE2","title":"Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Istituto Clinico Humanitas","startDate":"2020-01-30","conditions":"Hepatocarcinoma","enrollment":46},{"nctId":"NCT04131543","phase":"PHASE2","title":"Phase II Study With Cabozantinib in Patients With RET Positive NSCLC","status":"UNKNOWN","sponsor":"University of Bologna","startDate":"2019-08-07","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT01522443","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Mitoxantrone Plus Prednisone in Men With Previously Treated Symptomatic Castration-resistant Prostate Cancer","status":"TERMINATED","sponsor":"Exelixis","startDate":"2012-03","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":119},{"nctId":"NCT01605227","phase":"PHASE3","title":"Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100","status":"COMPLETED","sponsor":"Exelixis","startDate":"2012-07","conditions":"Prostate Cancer, Castration Resistant Prostate Cancer, Pain","enrollment":1028},{"nctId":"NCT01866293","phase":"PHASE1, PHASE2","title":"Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-05-28","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":11},{"nctId":"NCT01553656","phase":"PHASE1","title":"Dose-Finding Study of Cabozantinib (XL184) in Japanese Subjects With Advanced Cancer","status":"COMPLETED","sponsor":"Exelixis","startDate":"2011-02","conditions":"Solid Tumors, Cancer, NSCLC","enrollment":85},{"nctId":"NCT01100619","phase":"PHASE1","title":"A Drug-Drug Interaction Study of the Effects of XL184 (Cabozantinib) on Rosiglitazone in Subjects With Solid Tumors","status":"COMPLETED","sponsor":"Exelixis","startDate":"2010-04","conditions":"Papillary Thyroid Cancer, Follicular Thyroid Cancer, Huerthle Cell Thyroid Cancer","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["XL184"],"phase":"phase_3","status":"active","brandName":"Cabozantinib tablets","genericName":"Cabozantinib tablets","companyName":"Exelixis","companyId":"exelixis","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabozantinib is a multi-targeted tyrosine kinase inhibitor that blocks MET, VEGFR2, and AXL signaling to inhibit tumor growth and angiogenesis. Used for Metastatic renal cell carcinoma, Hepatocellular carcinoma, Medullary thyroid cancer.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}